The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

The facility to manufacture cell therapies for cancer research is part of the company's push to invest $3.5B in its U.S.

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to attack cancer.

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

Maryland Lt. Gov. Aruna Miller and other state officials cut the ribbon at a new AstraZeneca facility in Rockville Monday.

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

The FDA pushed back its decision date on Cytokinetics’ heart drug. Elsewhere, Repare Therapeutics licensed its drug discovery ...

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...